Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darcy Krueger

Neurology with Special Qualifications in Child Neurology Cincinnati, OH Medical Doctor

NPI 1427178284 CMS profile 110001

3333 Burnet Ave, Ml 5021, Cincinnati, OH 45229

Open in the dashboard

General payments

$45,449

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$75,702 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Darcy Krueger of Cincinnati, OH is reported in the CMS Open Payments database as having received $45,449 across 55 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $75,702 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,771 8
2024 General $65 1
2023 General $3,500 4
2021 General $1,840 4
2020 General $2,278 3
2019 General $33,994 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darcy Krueger
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Darcy Krueger were reported at $3,771. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Darcy Krueger Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $33,994 $262 $68–$1,313 $163
2020 $2,278 $188 $46–$1,222 $114
2021 $1,840 $183 $45–$1,356 $132
2022 $0 $229 $72–$1,177 $149
2023 $3,500 $269 $93–$1,195 $160
2024 $65 $300 $98–$1,428 $164
2025 $3,771 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $20,772 21 payments
  2. Greenwich Biosciences, Inc. $10,341 17 payments
  3. GW Research Limited $7,000 4 payments
  4. Biocodex, Inc. $3,500 4 payments
  5. Jazz Pharmaceuticals Inc. $2,804 8 payments
  6. Alexion Pharmaceuticals, Inc. $1,033 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,607 13 payments
  2. Consulting Fee $12,127 8 payments
  3. Travel and Lodging $5,237 19 payments
  4. Honoraria $2,653 1 payment
  5. Food and Beverage $826 14 payments
Products named General payments · program years 2019–2025
  1. AFINITOR $20,772 21 payments
  2. Epidiolex $20,145 29 payments
  3. DIACOMIT $3,500 4 payments
  4. KOSELUGO $1,033 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

229

Median for Neurology: 833

Drug cost

$502,643

Median for Neurology: $202,670

Branded share of claims

24%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Afinitor Everolimus Brand 20 $366,826
Vigabatrin Generic 14 $51,595
Everolimus Generic 19 $33,137
Sirolimus Generic 22 $32,065
Epidiolex Cannabidiol (Cbd) Brand 14 $16,458
Divalproex Sodium Er Divalproex Sodium Brand 21 $1,161
Risperidone Generic 17 $457
Topiramate Generic 34 $372
Sumatriptan Succinate Generic 19 $204
Olanzapine Generic 12 $198

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $65
$65 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record